Q-omics provides the consensus-scored EGILA profile across patient tissues and cancer cell-line models. EGILA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, EGILA is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, EGILA RNA expression shows 13,099 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where EGILA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EGILA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EGILA survival associations across molecular data types. EGILA RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EGILA RNA expression–survival associations across cancer types. High EGILA expression shows unfavorable associations in STAD, KICH, ACC and LGG, but favorable associations in LIHC and KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for EGILA RNA expression.
This table summarizes EGILA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EGILA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EGILA shows lower tumor expression in UCEC and CHOL and higher tumor expression in KIRC, COAD, HNSC and LUSC. The KIRC box plot shows higher EGILA RNA expression in tumor versus normal tissue (log2 FC = +0.264, t-test p < 0.001).
This table shows molecular features associated with EGILA in patient tissues and cancer cell lines. In patient samples, EGILA shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
